AstraZeneca PLC Earnings - Q2 2026 Analysis & Highlights
AstraZeneca reported strong first-half 2026 results with 6% total revenue growth (11% excluding generic headwinds), 11% core EPS growth, and positive Phase III data across six programs including three new molecular entities, while maintaining confidence in its $80 billion 2030 revenue ambition and outlining an ambitious post-2030 growth strategy anchored in transformative technology platforms including ADCs, bispecifics, cell therapies, and next-generation weight management assets.
Key Financial Results
Total revenue grew 6% in the first half of 2026, with product revenue also increasing 6%.
Excluding Farxiga and Brilinta impact, total revenue grew 11%, demonstrating underlying portfolio strength.
Core EPS increased 11% in the first half, in line with full-year guidance.
Core gross margin was 83% in the first half, with expectations for lower gross margin in the second half due to seasonal demand patterns for lower-margin medicines.
Alliance revenue increased 29%, reflecting higher profit shares from partnered medicines including Enhertu, Datroway, and Tezspire.
Core R&D expense increased 6% in the first half, representing 23% of total revenue.
Core SG&A expense increased 6% in the first half, driven by Baxfendy launch investments and pre-launch investments for tozorakimab.
Other operating income was $341 million in the first six months, consisting of royalties and small regional divestitures.
Capital expenditure was $1.5 billion in the first half, with CapEx expected to increase by around a third in 2026.
Deal-related payments totaled $3.3 billion, including milestone payments and the $1.2 billion upfront payment for CSPC collaboration.
Net debt increased by around $3.5 billion in the first half, primarily reflecting dividend payments and deal payments.
Business Segment Results
Oncology total revenues grew 15% in the first half to $14.1 billion, underpinned by double-digit growth in all major regions.
Growth in the US and Europe was particularly notable at 18% and 16%, respectively for Oncology.
Tagrisso delivered 6% growth in the second quarter to revenues of $1.9 billion, supported by double-digit growth in the US.
Calquence grew 16% in the quarter, generating more than $1 billion in revenue for the first time in a single quarter.
Imfinzi and Imjudo delivered growth of 25% in aggregate in the second quarter.
Enhertu delivered growth of 31% in the quarter and reported revenues of $888 million.
Truqap revenues of $233 million in the quarter represent growth of 37% over the prior year.
Datroway revenues of $55 million in the second quarter demonstrate growing demand in later-line EGFR-mutated lung cancer.
BioPharmaceuticals business total revenue declined by 5% to $11.2 billion in the first half, reflecting loss of exclusivity headwinds for Farxiga, Brilinta, and roxadustat.
Respiratory & Immunology total revenue grew by 11% in the quarter.
Fasenra grew 13% to $570 million, driven by its continued leadership of the IL-5 class.
Tezspire grew by 45% to $390 million, with strong performances in the United States and Europe.
Breztri continued on its positive trajectory, with 20% growth through $346 million.
Symbicort revenues of $671 million were down 8%, due to price pressure in the United States from a new generic competitor.
Saphnelo revenues increased 24% to $209 million, driven by share gains in the intravenous segment.
Farxiga declined by 90% overall, resulting in $1.8 billion of revenue for the quarter due to generic competition in the US.
Rare Disease total revenues grew by 11% in the first half to $4.9 billion, underpinned by double-digit growth across key medicines.
Ultomiris grew 12% in the second quarter, driven by patient demand across indications.
Strensiq grew 36% year-on-year, reflecting strong patient demand.
Koselugo continues to deliver strong global momentum, supported by expansion in adult patients with NF1-PN.
Capital Allocation
CapEx of $1.5 billion in the first half, with expectations for approximately one-third increase in 2026 total CapEx.
Key investments include a new ADC manufacturing facility in Singapore and several other strategic multi-year projects.
Deal-related payments totaled $3.3 billion, including milestone payments and upfront payments for business development transactions.
New BD transactions announced totaling just over $2 billion in upfront payments year-to-date, including the Dizal transaction.
Lease liabilities increased as the company opened its new Kendall Square R&D center in Cambridge.
Net debt increased by around $3.5 billion in the first half, primarily reflecting dividend payments and deal payments.
Milestone payments of approximately $2.5 billion expected for the full year relating to prior business development transactions.
Industry Trends and Dynamics
Strong demand for innovative medicines drove total revenue growth of 6% in the first half.
Loss of exclusivity headwinds for Farxiga, Brilinta, and roxadustat impacted BioPharmaceuticals segment performance.
Volume-based procurement in China continued to impact growth, though recent NRDL additions and new regulatory approvals in 2026 are expected to fuel future growth.
Emerging markets outside of China showed strong growth performance.
Global trend towards adoption of finite-duration treatments supports AMPLIFY as a significant growth driver.
Rapid establishment of MATTERHORN as the standard of care in gastric cancer in reimbursed markets.
Competitive entrants in muscle-invasive bladder cancer market, though VOLGA will continue to expand Imfinzi's reach.
Intense competition in EGFR-mutated lung cancer market, particularly in China with multiple EGFR inhibitors.
Chinese companies innovating at great speed and partnering with global companies to globalize development and commercialization.
Competitive Landscape
FLAURA2 holds around three quarters of the growing first-line combination segment in the highly competitive US market for EGFR-mutated lung cancer.
Calquence maintains its position as the leading BTK inhibitor in front-line CLL across major markets despite intense competition.
Enhertu maintains sustained market leadership in HER2-positive and HER2-low breast indications in major markets.
Tagrisso is the number one prescribed third-generation EGFR TKI globally approved across all stages of disease.
Zegfrovy in-licensing complements existing EGFR leadership and allows the company to bring differentiated treatment to patients with limited options globally.
Datroway has a differentiated profile in triple-negative breast cancer for patients not candidates for immunotherapy.
Sone-ve is the first Phase III trial to demonstrate an overall survival benefit with a Claudin 18.2-targeted antibody-drug conjugate in the second-line-plus setting.
Potential competition from longer-acting C5 inhibitors like Regeneron's cemdisiran may impact the C5 franchise.
Chinese companies expanding globally over time, requiring AstraZeneca to learn to compete with them.
Macroeconomic Environment
Price pressure in the United States reflected in Symbicort revenues declining 8% due to new generic competitor.
Most Favored Nation (MFN) pricing impact on pricing strategy across all launches, with US now referencing a basket of countries.
Funding for innovation needs to rise in line with a country's GDP per capita under the new MFN pricing reality.
Discussions with payers expected to take more time than in the past due to MFN pricing dynamics.
Growth Opportunities and Strategies
Six positive Phase III program readouts announced in the first half, including three new molecular entities.
30 major market approvals secured across diverse portfolio, including first approvals for Etcamah in breast cancer and Baxfendy in hypertension.
11 approved NMEs achieved since outlining target to achieve 20 by 2030.
Tozorakimab in COPD with highly clinically meaningful benefits in OBERON and TITANIA trials, with peak revenue expectation increased to more than $5 billion.
Efzimfotase alfa in HPP with first pivotal data for this new molecular entity.
Sone-ve in Claudin 18.2-positive gastric cancer as first wholly-owned ADC with overall survival benefit, with peak year revenue estimated between $3 billion and $5 billion.
Etcamah in first-line hormone receptor-positive breast cancer with emergent ESR1 mutations approved in Europe and Japan.
Baxfendy approved by US FDA for uncontrolled or resistant hypertension, with launch activities underway.
Zegfrovy in-licensing for exon 20 insertion mutations in EGFR-mutated lung cancer, already approved in US and China.
Comprehensive Phase III program initiated for elecoglipron in both obesity and type 2 diabetes following positive Phase IIb results.
EMBOLD program studying elecoglipron monotherapy in patients with obesity or overweight with or without type 2 diabetes.
ELUMINATE program with five Phase III trials evaluating elecoglipron as monotherapy and in combination with dapagliflozin.
ELEVATE program designed to demonstrate value of elecoglipron in heart failure with preserved ejection fraction and chronic kidney disease.
Phase III monotherapy trial initiated for AZD6234, a selective amylin receptor agonist, following Phase II APRICUS trial readout.
Laroprovstat Phase III readout expected in first half of 2027, with first fixed dose combination with rosuvastatin advancing into Phase III.
Sunakiment Phase II study readout with plans for Phase III discussions with partner Amgen.
Exclusive license agreement with CTTQ for TQC3721, an inhaled small molecule PDE3/4 inhibitor in Phase III trials in China for COPD.
16 Phase III trials across eight tumor types for next-generation IO bispecifics, including five in combination with ADCs.
AZD0120 and surovatamig with multiple Phase III trials underway across hematology and extended into autoimmune diseases.
Off-the-shelf and in vivo cell therapies being developed to reach more patients across more disease areas.
Three recent launches with peak-year revenue potential of more than $5 billion each: Datroway, Etcamah, and Baxfendy.
25 key Phase III trial readouts planned over the next 18 months.
Six numerical entities with pivotal data readouts expected in 2027 alone.
Saruparib in prostate cancer with significant opportunity in the $5 billion range.
CLARITY-Gastric02 study evaluating sone-ve in combination with capecitabine with or without rilvegostomig or nivolumab in first-line gastric cancer.
Opportunities to extend sone-ve into earlier-stage settings and other GI-based cancers including pancreatic and biliary tract cancers.
TROPION-Lung15 and SAFFRON trials due to read out later this year investigating combinations in post-TKI second-line setting.
TROPION-Lung14 aiming to bring combination of Datroway and Tagrisso into first-line setting.
VOLGA trial positive results for Imfinzi in muscle-invasive bladder cancer patients not candidates for cisplatin.
CLARITY-Gastric01 trial demonstrating overall survival benefit with sone-ve in previously treated advanced gastric cancer.
Ultomiris Phase III data in IgA nephropathy showing 43% reduction in proteinuria with significant reduction as early as 10 weeks.
Efzimfotase alfa Phase III pediatric trials demonstrating clinically meaningful improvement in bone health, function, and quality of life.
Eneboparatide in hypoparathyroidism demonstrating maintenance of serum calcium and restoration of normal bone turnover.
Anselamimab in kappa light chain amyloidosis showing 62% reduction in all-cause mortality and 71% reduction in cardiovascular hospitalization.
Baxfendy primary aldosteronism trial accruing very rapidly with accelerated timeline.
Combination strategy with dapagliflozin including zibo-dapa, balci-dapa, and baxdrostat in high-risk patient populations.
Zibo-dapa in proteinuric CKD recruiting very fast, showing high unmet medical need.
Balci-dapa in heart failure patients with low EGFR where mortality is very high.
Baxdrostat in combination with dapagliflozin in chronic kidney disease and hypertension.
Ability to combine products through portfolio to defend franchises and build beyond current position.
Financial Guidance and Outlook
Total revenue expected to increase by mid-to high-single digit percentage for the full year 2026.
Core EPS expected to increase by low-double digit percentage at constant exchange rates for the full year 2026.
Core gross margin expected to be stable to slightly higher versus 2025 for the full year.
R&D expenses expected to be at the upper end of the low-20s percentage range for the full year.
Core finance costs expected to be higher in the second half compared to the first half due to refinancing activities.
Milestone payments of approximately $2.5 billion expected for the full year relating to prior business development transactions.
Working capital effects from US loss of exclusivity for Farxiga expected to persist through remainder of year before normalizing.
$80 billion revenue ambition for 2030 based on strength of broad and diversified portfolio, described as risk-adjusted forecast.
If everything worked, revenue would be above $80 billion, indicating conservative risk adjustment.
Expected setbacks to happen as part of risk-adjusted planning.
Confidence in reaching 2030 target underpinned by exceptional quality
